TNF and B-cell chronic lymphocytic leukemia: Rituximab is currently approved for the treatment of relapsed or refractory non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), and in combination with methotrexate (MTX) for the treatment of Rheumatoid Arthritis (RA) patients who inadequately respond to one or more anti-tumor necrosis factor (anti-TNF) therapies.